Optimal Dosing of Omeprazole in Neonates

NCT ID: NCT01657578

Last Updated: 2012-10-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 55 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-06-30
• Study Completion Date: 2012-02-29

Brief Summary

"The principal aim of this trial is to determine the minimum effective dose of omeprazole in neonates with GERD objectively diagnosed by a 24-h intra-oesophageal pH monitoring (pHmetry), to obtain a short-term efficacy in the pHmetry of control performed 72 hrs ± 24 after initiation of omeprazole.

The secondary objectives of the study were: (1) to assess the efficacy of omeprazole upon other pHmetry parameters, (2) to characterize the population pharmacokinetics and pharmacogenetics of omeprazole, (3) to evaluate the effect of omeprazole upon oro-pharyngeal pH monitoring and (4) to assess the short-term safety of use of omeprazole in neonates."

Detailed Description

"Omeprazole is a proton pump inhibitor increasingly prescribed in the neonatal population for gastroesophageal reflux disease (GERD) complicated or not by the presence of esophagitis. Although extensively evaluated in adults, optimal dosing schemas, efficacy and safety have not been determined in the neonatal population where its prescription remains off-label. The study is a double blind trial that was designed using a Bayesian sequential analysis approach. The principle of this approach is to identify the adequate drug dosage to obtain a level of efficacy as close as possible to a predetermined target level of efficacy in the population. In this study, five different dosages of omeprazole are tested (1, 1,5, 2, 2,5, 3 mg/kg/day) and a target probability of successful treatment of 95% has been chosen. To assess the influence of gestational age on omeprazole's efficacy, analysis was stratified on 3 groups: (1) neonates of less than 32 weeks gestational age (GA), (2) neonates born between 32 and 35 weeks of GA, (3) neonates of more than 36 weeks of GA.

A total maximum number of 90 neonates is expected to be included (30 neonates per group).

Patients' participation in the study ends after completion of the pHmetry of control that is 72 ±24 hours after omeprazole initiation.

Patients in the study will all benefit for the management of their GERD from non-pharmacological therapies such as adequate positioning and use of available thickening agents for formula The only pharmacologic agent authorised during study for treating GERD is omeprazole. All other available GERD treatments will not be prescribed."

Conditions

Gastroesophageal Reflux Disease (GERD)

Keywords

neonates; reflux disease; population pharmacokinetics, omeprazole

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

neonates of less than 32 weeks gestational age

omeprazole

Group Type: EXPERIMENTAL

Omeprazole

Intervention Type: DRUG

administration of Omeprazole

neonates born between 32 and 35 weeks of GA

omeprazole

Group Type: EXPERIMENTAL

Omeprazole

Intervention Type: DRUG

administration of Omeprazole

neonates of more than 36 weeks of GA

omeprazole

Group Type: EXPERIMENTAL

Omeprazole

Intervention Type: DRUG

administration of Omeprazole

Interventions

Omeprazole

administration of Omeprazole

Intervention Type: DRUG

Other Intervention Names

administration of Omeprazole

Eligibility Criteria

Inclusion Criteria

• Full-term neonates or preterm neonates with a postmenstrual age >/= 35 weeks
• Presenting abnormal pHmetry (= percentage of the entire record that intra-oesophageal pH is <4 is superior or equal to 5%)
• Patient must receive discontinuous oral feedings
• If proton pump inhibitors or other pharmacologic antireflux therapies had already commenced, these had to be withdrawn 7 days before baseline recordings
• In-patient in Neonatal Intensive Care Unit or Neonatology Unit of the Robert Debré University Hospital
• Both parents sign written informed consent form
• Affiliated to social security

Exclusion Criteria

• Patients under proton pump inhibitors (PPI) treatment or that have discontinued PPI treatment less than 7 days before inclusion
• Patients with acute gastrointestinal disease (diarrhoea)
• Patients than present leucopenia or thrombocytopenia (value half the normal value for age)
• Patients that present aspartate and alanine aminotransferase values twice the upper limit of normal
• Patients that present renal and hepatic failure
• Newborns presenting galactosemia, glucose-galactose malabsorption, deficiency in lactase enzymes
• Co-administration of atazanavir and ritonavir
• Patients allergic to omeprazole or to any other ingredients in the medicine

• Minimum Eligible Age: 35 Weeks
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Evelyne Jacqz-Aigrain, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

Hospital Robert Debre

Paris, , France

Countries

France

Other Identifiers

2006-005335-16

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

P 051043

Identifier Type: -

Identifier Source: org_study_id